Trial ID or NCT#



not recruiting iconNOT RECRUITING


In this study we plan to study the combination of ZD6474, a dual inhibitor of EGFR and VEGFR-2 with anastrozole in the neoadjuvant setting for patients with Stage I-III breast cancer. The aim is to overcome mechanisms of resistance and simultaneously block multiple critical signaling pathways known to stimulate breast cancer.

Official Title

Randomized Phase 2 Trial of Anastrozole Combined With Novel Agent ZD6474 in the Neoadjuvant Treatment of Postmenopausal Patients With Hormone Receptor-Positive Breast Cancer

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No


Bruce Daniel
Bruce Daniel
Professor of Radiology (Body Imaging) and, by courtesy, of Bioengineering
Robert W. Carlson
Frederick M. Dirbas, MD
Frederick M. Dirbas, MD
Surgical oncologist, Breast surgeon
Associate Professor of Surgery (General Surgery)
Irene Wapnir, MD
Irene Wapnir, MD
Surgical oncologist, Breast surgeon, Breast specialist
Professor of Surgery (General Surgery)

Contact us to find out if this trial is right for you.


Marcy Chen
(650) 723-8686